X
[{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Azura Ophthalmics Raises US$20 Million for Registration Studies for Treatment of Leading Cause of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"ISRAEL","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Azura Ophthalmics"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"CUREator","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Azura Ophthalmics Secures Grant to Evaluate AZR-MD-001 for Improved Vision Quality Related to Contact Lens Discomfort","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"ISRAEL","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Azura Ophthalmics"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Azura Ophthalmics"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
AZR-MD-001 0.5% meets co-primary efficacy endpoints, making it the first investigational drug to show significant improvements in both signs and symptoms of Meibomian Gland Dysfunction.
Lead Product(s):
AZR-MD-001
Therapeutic Area: Ophthalmology
Product Name: AZR-MD-001
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 17, 2022
Details:
The grant will support Azura’s two-stage study evaluating the safety, tolerability and efficacy of the company’s lead clinical candidate, AZR-MD-001, in patients with contact lens discomfort (CLD) who show evidence of Meibomian gland dysfunction (MGD).
Lead Product(s):
AZR-MD-001
Therapeutic Area: Ophthalmology
Product Name: AZR-MD-001
Highest Development Status: Phase II/ Phase III
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
CUREator
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Funding
September 07, 2022
Details:
On the back of encouraging Phase 2 data to date proceeds from the funding round will be used to advance Azura’s lead product candidate AZR-MD-001 through a registration study for the treatment of MGD.
Lead Product(s):
AZR-MD-001
Therapeutic Area: Ophthalmology
Product Name: AZR-MD-001
Highest Development Status: Phase II/ Phase III
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
OrbiMed
Deal Size: $20.0 million
Upfront Cash: Undisclosed
Deal Type: Financing
October 22, 2020